Yuheng Pharmaceutical Co., Ltd. and Wuxi Pharmaceutical Co., Ltd. signed a strategic cooperation on new chemical class 1.1 drugs

Yuheng Pharmaceutical Co., Ltd signed a risk sharing cooperative development agreement with Wuxi Pharmaceutical Co., Ltd The two sides intend to achieve win-win cooperation in the field of pharmaceutical research and development through complementary advantages and strong alliance The company will select the target point, with the help of the capability of the R & D platform for new chemical drugs of Wuxi apptec, devote itself to the R & D of new chemical drugs of category 1.1 with independent intellectual property rights, and obtain the clinical trial approval from the State Food and drug administration The treatment area is mainly for lung diseases (including tumor and respiratory tract indications) Yuheng Pharmaceutical Co., Ltd has selected an anti-tumor biological drug product to cooperate in various aspects such as preclinical pharmaceutical research, preclinical animal experimental research, product registration application at all stages, clinical trial, clinical sample production, marketing license and sales, etc in the way of risk sharing and revenue sharing Yuheng pharmaceutical, as the main investor of the agreement products, pays the R & D expenses of Wuxi apptec Through the agreement, Yuheng pharmaceutical can enhance the company's innovative drug R & D strength by virtue of the R & D platform advantages of Wuxi apptec, which is conducive to further enriching the company's product line and improving the company's future product competitiveness and profitability Lu Qiang, Yuheng pharmaceutical: seize the opportunity to enter the field of Biopharmaceutics excerpt: on January 24, biological exploration, Yuheng pharmaceutical announced that it plans to raise no more than 6 billion yuan of funds through non-public offering of shares, of which 2.389 billion yuan will be used to acquire 85.01% of shares in Shanxi Pude Pude pharmaceutical has 153 varieties, but limited by its sales ability, there are still a large number of outstanding varieties that have not been sold on a large scale at present, while Yuheng pharmaceutical has outstanding varieties integration sales ability, which can produce synergistic effect Yuheng pharmaceutical was founded in March 2000 and listed on the SME Board of Shenzhen Stock Exchange in June 2010 The company is mainly engaged in drug production and drug agent sales business Its products are mainly prescription drugs, with 40 drug registration approvals, 23 main products, covering orthopedic drugs, rheumatic drugs, anti-tumor drugs and other fields Its orthopedic products, deer and melon polypeptide, have developed into a large variety of 1 billion yuan, with a market share of more than 70% In 2014, Yuheng pharmaceutical's total operating revenue was about 1.905 billion, up 45.72% year on year, and the net profit attributable to the parent company was 444 million, up 95.69% year on year In recent years, Yuheng Pharmaceutical Co., Ltd has been purchasing continuously As early as February 2009, Yuheng Pharmaceutical Co., Ltd obtained 50% equity of Guangzhou new flower city with an agreement of 70 million yuan, and then acquired 20% and 30% equity of Guangzhou new flower city with a price of 33.8 million yuan and 150 million yuan in 2011 and 2015 respectively, making it a wholly-owned subsidiary In April 2012, Yuheng pharmaceutical raised 210 million yuan to increase dandelion pharmaceutical, holding 75% of the latter's equity In March 2013, the company acquired 100% equity of Aonuo (China) Pharmaceutical Co., Ltd with a total of 420 million yuan in the form of partial over raising In January 2014, Yuheng purchased 62% of the capital stock of Shanghai Huatuo with RMB 698 million, and then increased the shareholding ratio to 98.8% in February, including the latter's cardiac protection leading product, sodium creatine phosphate for injection, into the capsule In May 2014, Tibet sunshine, a wholly-owned subsidiary of Yuheng pharmaceutical, acquired 100% equity of Nanjing Wanchuan with a total amount of RMB 797 million Seizing the opportunity to enter the field of biological medicine for nearly two years, Yuheng pharmaceutical has enriched its product types through internal R & D, external introduction, foreign M & A and other ways So, in addition to acquisition, what new strategic layout does Yuheng have in the future? Apart from the three areas that we are good at, are there any plans to enter other disease areas? Nowadays, biopharmaceutics have become an important part of the pharmaceutical field Will Yuheng seize the opportunity and seek new development? With these questions, the reporter interviewed Dr LV Qiang, vice president and chief scientific officer of Yuheng pharmaceutical, in 2015 (the fifth) antibody drug and new drug research and Development Summit In 2015, Yuheng's main development strategy is "product leading", first of all, combing, repositioning and clinical promotion of existing products, then focusing on the research and development of innovative drugs; in addition, the company will have a new layout in the field other than drugs In addition to the strategic layout of "product leading", the company will continue to further integrate resources (including product line, R & D strategy, etc.) through M & A In addition to the existing product line, Yuheng is also actively laying out other disease areas, including the field of nerves, infectious diseases, etc However, in addition to the classification according to the traditional treatment field, Yuheng is taking its own innovative mode, hoping to find a unique way by effectively integrating the existing clinical resources and market resources Participation in the antibody summit really shows that Yuheng attaches great importance to the antibody market Antibody market is a sunrise industry in the field of Biopharmaceutics, but the domestic antibody market is relatively backward How to achieve innovation in line with China's environment under the background of global antibody industry is one of the main problems facing the pharmaceutical industry In the rapid development stage of antibody industry, Yuheng is bound to seize the opportunity Prior to that, Yuheng has signed the framework agreement on strategic cooperation in biomedicine with Wuxi apptec, which will invest 1 billion yuan to establish macromolecular pipelines, including the layout of antibody field   In the special interview session with the theme of "bio pharmaceutical ecosystem: research and development technology, cooperation and innovation, market, policy and other multi-faceted analysis", LV Qiang said that Yuheng pharmaceutical's layout of bio pharmaceuticals has just begun, with the foreshadowing of product industrialization and marketization by Wuxi apptec, and hopes to cooperate with the academic community in the early stage of product development, and take the "industry university research" alliance The road of development The biggest characteristic of Yuheng pharmaceutical industry is that it can make full use of capital market and development platform to walk out of the innovation road of medium-sized enterprises In addition, Lu Qiang said in the interview that Yuheng is a company that is aggressive and encourages innovation The leaders of the company can give full authorization to the senior management to promote the project efficiently In addition, there are many young employees in the company, who can often encounter some unexpected surprises The atmosphere of concerted efforts makes everyone full of energy "Product leading" will be the development strategy that Yuheng has always adhered to Only by making good products can the company achieve sustainable development Guided by the strategic slogan of "gathering elites, breaking out energy and creating value", the company is striving to create the maximum value for patients and employees About LV Qiang, currently vice president and chief scientific officer of Yuheng pharmaceutical industry He graduated from Beijing University with a Ph.D in biochemistry from Brandeis University The 863 project leader and major special judge for new drug creation (2014) has successively worked in Wyeth pharmaceutical, Novartis pharmaceutical, Shanghai Pharmaceutical mingkant new drug development Co., Ltd and Jiangsu Yangtze River Pharmaceutical Group At Wyeth Pharma, led the pain project team to develop multiple clinical compounds including entering phase II In Novartis, as the founder of ion channel and Central Laboratory of Cytotoxicology, he is responsible for the development and research of Novartis global ion channel drugs, involved in many treatment fields and jointly led the heart safety assessment advisory group of Novartis After returning to China in 2008, he was responsible for the establishment of the R & D biology department and the biopharmaceutical Department of Shanghai yaomingkant new drug development Co., Ltd., comprehensively presided over the R & D work of Yangtze River Pharmaceutical Group and Its Affiliated Shanghai Haiyan Pharmaceutical Technology Co., Ltd., as well as the international cooperation of the group's affiliated Pan Pacific biopharmaceutical Co., Ltd Yuheng Pharmaceutical Group was founded in March 2000 It is a high-tech enterprise group with big health industry as the main line and pharmaceutical industry as the core, including chemical medicine, traditional Chinese medicine, OTC, health products, etc., covering scientific research, production, marketing and other fields In 2010, Yuheng pharmaceutical was successfully listed and entered the fast lane of product management and capital management Since its listing, the company has gradually formed a dual engine growth mode of focusing on both chemical medicine and Chinese patent medicine, and has entered into cardio cerebrovascular, anti-tumor and other treatment fields from the narrow orthopedic medical market Securities code: 002437 securities abbreviation: Yuheng pharmaceutical Announcement No.: 2015-072 announcement of Harbin Yuheng Pharmaceutical Co., Ltd on signing the strategic cooperation agreement on chemical innovative drugs with Shanghai yaomingkant new drug development Co., Ltd the company and all members of the board of directors guarantee that the information disclosure is true, accurate and complete, There is no false record, misleading statement or major omission Special tips: 1 The strategic cooperation agreement on chemical innovative drugs (hereinafter referred to as "the agreement") is only a framework and intentional agreement on the willingness and basic principles of cooperation between the two parties The following specific cooperation projects will be jointly executed by both parties through signing a legally binding product R & D agreement 2 If the specific target of future cooperation between the two parties is not listed in this agreement, the company will strictly perform the obligation of information disclosure in accordance with the Listing Rules of Shenzhen Stock Exchange and the articles of association, and after relevant matters are determined Investors are requested to make prudent decisions and pay attention to investment risks I background of signing the agreement: January 23, 2015, The company has signed the framework agreement on strategic cooperation of biomedicine (hereinafter referred to as the framework agreement) with Shanghai Pharmaceutical Kant new drug development Co., Ltd (for details, please refer to China Securities Journal, securities times and http://www.cninfo.com.cn, the information disclosure media designated by the CSRC on January 24, 2015 Announcement No 2015-007 of the seventh meeting of the third board of directors After the signing of the framework agreement, the company and Wuxi apptec held many negotiations on the framework agreement, and signed this Agreement on May 22, 2015 By signing this agreement, the company can enhance its R & D strength in the field of chemical drugs, especially in the field of innovative drugs for lung diseases, by virtue of the R & D platform advantages of Wuxi apptec, which is conducive to further enriching the company's product line, improving the competitiveness and profitability of the company's product line in the future, and meeting the company's long-term development plan II Introduction to the counterparty: Shanghai Wuxi apptec new drug development Co., Ltd., a subsidiary of Wuxi apptec new drug development Co., Ltd Wuxi apptec new drug development Co., Ltd is the world's leading pharmaceutical, biotechnology and medical device R & D open capability and technology platform company It has operating entities in China and the United States, providing a series of comprehensive laboratory R & D, research and production services to global pharmaceutical companies, biotechnology companies and medical device companies, The scope of service runs through the whole process from drug discovery to market In recent years, Wuxi apptec new drug development Co., Ltd has added a series of integrated services, Including analysis service, biological analysis service, process research, process R & D service, API production service, drug metabolism and kinetics service, R & D biology, pharmacology, preparation, toxicology, genome service, biological preparation production service, antibody and biological diagnostic reagent production and sales service, clinical R & D and product registration service, etc Shanghai yaomingkant new drug development Co., Ltd., company type: limited liability company (Sino foreign joint venture); company domicile: China (Shanghai) free trade